Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cyclobenzaprine/etodolac - Apsen Farmaceutica

Next Previous
Drug Profile

Cyclobenzaprine/etodolac - Apsen Farmaceutica

Alternative Names: Etodolac/cyclobenzaprine - Apsen Farmaceutica

Latest Information Update: 22 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Apsen Farmaceutica
  • Class Amines; Analgesics; Antirheumatics; Anxiolytics; Behavioural disorder therapies; Dibenzocycloheptenes; Drug withdrawal therapies; Indoleacetic acids; Indoles; Muscle relaxants; Nonsteroidal anti-inflammatories; Small molecules
  • Mechanism of Action Alpha 1 adrenergic receptor antagonists; Cyclooxygenase inhibitors; Histamine H1 receptor antagonists; Serotonin 2A receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Postoperative pain

Most Recent Events

  • 09 Feb 2023 Apsen Farmaceutica terminates a phase III trial in Postoperative pain (In adults, In elderly, In Volunteers, Combination therapy) in Brazil due to recruitment difficulty (NCT03127592)
  • 29 Nov 2022 Cyclobenzaprine/etodolac is still in phase III trials for Postoperative pain (In volunteers) in Brazil (NCT03127592)
  • 05 Oct 2020 Phase-III clinical trials in Postoperative pain (In volunteers) in Brazil (unspecified route) (NCT03127592)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top